COPENHAGEN (Reuters) -Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying people with obesity or overweight treated with the drug achieved a 22% weight loss after 36 weeks.
Shares jumped on the release and traded up 7% at 1040 GMT.
Amycretin targets the same gut hormone that Wegovy mimics, known as GLP-1, but also a pancreas hormone called amylin that affects hunger.
“The results seen in the trial support the weight lowering potential of this novel unimolecular GLP-1 and amylin receptor agonist, amycretin, that we have previously seen with the oral formulation,” Novo Nordisk’s head of development Martin Lange said in a statement.
Novo is also developing amycretin as a weight-loss pill, which helped obese participants lose 13.1% of their weight after 12 weeks of treatment in an early-stage study.
The company said in September it plans to decide on further studies for amycretin after data from the trial with the subcutaneous version.
(Reporting by Stine Jacobsen, editing by Louise Rasmussen)
Comments